- Home
- BCLI
as 12-18-2024 4:00pm EST
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 9.1M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 112.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $11.85 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Brainstorm Cell Therapeutics Inc. (BCLI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lebovits Chaim | BCLI | President & CEO | Sep 30 '24 | Buy | $1.83 | 23,836 | $11,308.34 | 1,186,865 |
Latest Brainstorm Cell Therapeutics Inc. News
BCLI Breaking Stock News: Dive into BCLI Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
PR Newswire
15 days ago
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
PR Newswire
16 days ago
BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
PR Newswire
a month ago
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
a month ago
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
PR Newswire
2 months ago
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR Newswire
2 months ago
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
PR Newswire
2 months ago
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
Compare BCLI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCLI Brainstorm Cell Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.